CAJ | 학술논문

目的分析并确定1个抗肌萎缩蛋白病(dystrophinopathy)家系的临床、分子病理及遗传学特征.方法收集先证者及其家系成员的临床资料,对先证者行肌肉活体组织检查,采用抗层黏连蛋白α2(1aminin α2,又称merosin)、抗emerin蛋白、抗肌萎缩蛋白(dystrophin)中央棒状区(Dys1)、C′末端(Dys2)、N′末端(Dys3)单克隆抗体行免疫组织化学染色;提取外周血基因组DNA,采用多重连接探针扩增(MLPA)进行抗肌萎缩蛋白Duchenne型肌营养不良(DMD)基因检测.结果该家系中包括先证者在内共有3例患者临床诊断为肌营养不良,均无腓肠肌肥大,但病情重、进展较快,同时先证者肌肉活体组织检查行免疫组织化学染色提示dystrephin蛋白部分缺失,merosin、emerin染色呈阳性表达.MLPA检测显示先证者DMD基因第45～54外显子缺失,其母在第45～54外显子区域为杂合性缺失.结论该家系中的先证者DMD基因为第45～54外显子缺失,突变基因来自母亲,其母为表型正常的携带者.dystrophin蛋白表达异常是造成抗肌萎缩蛋白病表型的病理基础,其临床后果不仅取决于dystrophin蛋白表达缺失的程度,还取决于DMD基因缺失区域的功能.
목적 분석병학정1개항기위축단백병(dystrophinopathy)가계적림상、분자병리급유전학특정.방법 수집선증자급기가계성원적림상자료,대선증자행기육활체조직검사,채용항층점련단백α2(1aminin α2,우칭merosin)、항emerin단백、항기위축단백(dystrophin)중앙봉상구(Dys1)、C′말단(Dys2)、N′말단(Dys3)단극륭항체행면역조직화학염색;제취외주혈기인조DNA,채용다중련접탐침확증(MLPA)진행항기위축단백Duchenne형기영양불량(DMD)기인검측.결과 해가계중포괄선증자재내공유3례환자림상진단위기영양불량,균무비장기비대,단병정중、진전교쾌,동시선증자기육활체조직검사행면역조직화학염색제시dystrephin단백부분결실,merosin、emerin염색정양성표체.MLPA검측현시선증자DMD기인제45～54외현자결실,기모재제45～54외현자구역위잡합성결실.결론 해가계중적선증자DMD기인위제45～54외현자결실,돌변기인래자모친,기모위표형정상적휴대자.dystrophin단백표체이상시조성항기위축단백병표형적병리기출,기림상후과불부취결우dystrophin단백표체결실적정도,환취결우DMD기인결실구역적공능.
Objective To analyze and determine the clinical, molecular pathology and genetic features of a Chinese family with dystrophinopathy. Methods Clinical data of the proband and his family members were collected. Immunohistochemistry staining was performed on muscular biopsy tissues with antimerosin, emerin and the N, C and central rod domains of dystrophin. Genomic DNA was extracted using standard procedures from the peripheral blood leukocytes. Multiplex ligation-dependent probe amplification (MLPA) was used to test Duchenne muscular dystrophy (DMD) gene to determine the ways and sites of genetic mutation, and analyze the relationships between genotype and phenotype. Results Patients from this family were clinically diagnosed as muscular dystrophy, and they presented serious manifestations although the immunohistochemistry analysis for the proband exhibited partial loss of dystrophin staining, and positive expression with merosin and emerin. Further test with MLPA detected the loss of exons 45--54 in DMD gene in the proband, while his mother had heterozygositic loss in exons 45--54. Conclusions The losses of exons 45--54 in the proband are all derived from his mother, who carries genetic mutation with normal phenotype. He has been diagnosed as dystrophinopathy. At the same time, his partial loss of dystrophin is not parallel to the out-of-frame mutation of the gene and his severe clinical manifestations. Abnormal expression of dystrophin is the pathological basis for dystrophinopathy phenotype. Its clinical outcome depends not only on the degree of the protein expression, but also on the function of the sites where the DMD gene less occurs.